Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer
Lung cancer is one of the deadliest and most common malignancies in the world, representing one of the greatest challenges in cancer treatment. Immunotherapy is rapidly changing standard treatment schedule and outcomes for patients with advanced malignancies. However, several ongoing studies are sti...
Saved in:
Main Authors: | Carmine Carbone, Geny Piro, Vincenzo Di Noia, Ettore D’Argento, Emanuele Vita, Miriam Grazia Ferrara, Sara Pilotto, Michele Milella, Giovanni Cammarota, Antonio Gasbarrini, Giampaolo Tortora, Emilio Bria |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Mediators of Inflammation |
Online Access: | http://dx.doi.org/10.1155/2019/7652014 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Facial Papulopustular Eruption during the COVID-19 Pandemic in Patients Treated with EGFR Inhibitors
by: Eleonora De Luca, et al.
Published: (2024-01-01) -
The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltration
by: Chiara Cencioni, et al.
Published: (2025-01-01) -
Smoking, DNA Adducts and Number of Risk DNA Repair Alleles in Lung Cancer Cases, in Subjects with Benign Lung Diseases and in Controls
by: Marco Peluso, et al.
Published: (2010-01-01) -
EGFR-Mutant Non-small Cell Lung Cancer: State-of-the-Art and Future Perspectives
by: Antonio Rossi, et al.
Published: (2022-12-01) -
Postoperative Lung Function Advantages in Pulmonary Segmentectomy for Early‐Stage Lung Cancer
by: Ernesto Crisafulli, et al.
Published: (2025-01-01)